0001493152-26-014271 | 10-K | XBRL Viewer

Print Document

Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)												12 Months Ended
	Jan. 01, 2026	Aug. 01, 2025	Jul. 11, 2025	Jul. 08, 2025	Jun. 24, 2025	May 13, 2025	May 01, 2025	Apr. 11, 2025	Mar. 20, 2025	Mar. 07, 2025	Feb. 03, 2025	Dec. 31, 2025	Dec. 31, 2024	Nov. 05, 2024	Nov. 04, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross proceeds warrants					$ 10,000,000.0								$ 2,672,500
Fair value					265,957
Additional issuance costs					$ 74,000
Stock based compensation expense												222,831	705,567
Unrecognized stock-based compensation expense												$ 208,316	$ 321,893
Weighted average period			3 years									1 year 10 months 24 days	1 year 3 months 18 days
Exercise price				$ 1.00
Gross proceeds												$ 1,999,791
Warrant term												5 years
Other costs												$ 290,317	212,102
Proceeds from issuance of common stock													1,354,404
Inducement Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price				$ 0.67
Other fees				$ 41,852
Number of shares of common stock issued pursuant to the holder's exercise of existing warrants percentage rate				200.00%
March 2025 PreFunded Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price												$ 0.0001
December 2023 Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross proceeds warrants			$ 201,296
Private Placement [Member] \| March 2025 PreFunded Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price										$ 0.0001
Warrant purchase										2,105,265
Transaction costs												$ 290,317
Placement fees												199,863
Other fees												64,312
Other costs												$ 26,142
Private Placement [Member] \| March 2025 Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant purchase										2,105,265
Private Placement [Member] \| March 2025 Common Warrants And Prefunded Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price										$ 0.9499		$ 1.00		$ 1.00	$ 2.06
Warrant purchase														957,200
Gross proceeds										$ 2,000,000.0
Transaction costs										$ 53,890
Research and Development Expenses [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock based compensation expense												$ 10,345	61,789
General and Administrative Expenses [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock based compensation expense												212,486	643,778
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant modification costs				$ 1,762,756
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase of warrants			377,964		426,829
Exercise price			$ 0.59
Other costs												175,222	3,408,613
Proceeds from issuance of common stock												$ 2,051,852	$ 2,514,088
Series A2 Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant purchase				957,200
Series A3 Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant purchase				2,105,265
Series A4 Common Stock [Member] \| Inducement Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price				$ 0.67
Warrant purchase				6,124,930
Transaction costs				$ 175,222
Warrant term				5 years
Proceeds from issuance of common stock				$ 2,051,852
Cash fee paid				$ 133,370
2022 Omnibus Equity Incentive Plan [Member] \| Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares increased	705,958
2022 Omnibus Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized												382,122
Available for future issuance												377,965
Marketing Agreements [Member] \| Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued period of shares, common stock		160,000				100,000	100,000	100,000	100,000		60,000
Prepaid expense		$ 29,600				$ 51,800	$ 51,800	$ 77,000	$ 70,100		$ 81,600
Equity Purchase Agreement [Member] \| ELOC Shares [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Gross proceeds warrants					$ 10,000,000.0

Insider Trading Arrangements	12 Months Ended
Insider Trading Arrangements	Dec. 31, 2025
Insider Trading Arrangements [Line Items]
No Insider Trading Flag	true

Pay vs Performance Disclosure - USD ($)	12 Months Ended
Pay vs Performance Disclosure - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (24,952,378)	$ (9,413,435)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Segment Reporting (Details Narrative)	12 Months Ended
Segment Reporting (Details Narrative)	Dec. 31, 2025 Segment
Segment Reporting [Abstract]
Number of operating segment	1
Number of reporting segment	1

In-Process Research and Development

12 Months Ended

Dec. 31, 2025

Research and Development [Abstract]

In-Process Research and Development

Note 4 – In-Process Research and Development

In December of 2022, in connection with a business combination, the Company recorded an indefinite-lived intangible asset related to in-process research and development (“IPR&D”). ASC 350 requires that intangible assets with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. During the year ended December 31, 2025, management determined that it was more likely than not that the Company’s single reporting unit’s fair value was below its carrying amount, due to a significant and sustained decline in the Company’s market capitalization, therefore an impairment test was performed on the Company’s IPR&D intangible asset.

Current limitations on accessing significant capital in what is currently a risk averse environment for biotech (as evidenced by decreased investor appetite for risk, market volatility, regulatory uncertainty from a changing Food and Drug Administration and a challenging economic environment), resulted in a sustained decline in the Company’s market capitalization, and the Company’s ability to further finance the development of its drug candidates to the next milestone could be adversely impacted. Accordingly, the Company determined that the carrying value of its IPR&D intangible asset was not recoverable and it was fully impaired. Therefore, the Company recorded an $18.6 million impairment charge, reflected within operating expenses in the consolidated statements of operations for the year ended December 31, 2025.

Stockholders’ Equity (Deficit) (Tables)

12 Months Ended

Dec. 31, 2025

Accumulated Other Comprehensive Income (Loss) [Line Items]

Schedule of Stock Options Granted

The grant date fair value of stock options granted during the years ended December 31, 2025 and 2024 was determined using the Black Scholes method, with the following assumptions used:

Schedule of Stock Options Granted

	For the Years Ended
	December 31,
	2025			2024
Fair value of common stock on date of grant or modification		$0.13 - $0.59		N/A
Risk free interest rate		3.55% - 4.09	%	N/A
Expected term (years)		0.24 - 9.75		N/A
Expected volatility		78.7% - 161.5	%	N/A
Expected dividends		0.00	%	N/A

Schedule of Stock Option Activity

A summary of the option activity for the year ended December 31, 2025 is presented below:

Schedule of Stock Option Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value

Outstanding, January 1, 2025		9,612		$	2,248.58
Granted		377,964			0.59
Exercised		-			-
Expired		(219	)		1,760.50
Outstanding, December 31, 2025		387,357		$	55.67		9.4	$	-

Exercisable, December 31, 2025		8,045		$	2,605.21		5.1	$	-

Schedule of Information Related to Stock Options

The following table presents information related to stock options as of December 31, 2025:

Options Outstanding				Options Exercisable
				Weighted
		Outstanding		Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Options		In Years		Options
$	0.59		377,964		-		-
$	152.50		4,157		7.4		2,916
$	738.50		286		7.1		191
$	791.00		38		7.2		26
$	1,760.50		1,060		1.2		1,060
$	3,965.50		37		6.5		37
$	4,053.00		2,095		3.3		2,095
$	5,726.00		1,720		5.5		1,720
			387,357		5.1		8,045

Summary of Warrant Activity

A summary of the warrant activity for the year ended December 31, 2025 is presented below:

Summary of Warrant Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Warrants			Price		In Years		Value

Outstanding, January 1, 2025		1,747,093		$	59.59
Issued ^[1]		8,230,195			0.75
Repriced - Old ^[2]		(957,200	)		2.06
Repriced - New ^[2]		957,200			1.00
Repriced - Old ^[3]		(957,200	)		1.00
Repriced - New ^[3]		957,200			0.67
Repriced - Old ^[4]		(2,105,265	)		1.00
Repriced - New ^[4]		2,105,265			0.67
Forfeited		(3,050	)		12.50
Exercised^[1]		(3,062,465	)		0.67
Outstanding, December 31, 2025		6,911,773		$	15.34		4.48	$	-

Exercisable, December 31, 2025		6,911,573		$	15.29		4.48	$	-

[1]	Warrants issued and exercised exclude 2,105,265 March 2025 Pre-Funded Warrants with an exercise price of $0.0001.
[2]	Warrants represent the reset of the exercise price of certain November 2024 warrants to purchase 957,200 shares of common stock from $2.06 to $1.00 per share.
[3]	Warrants represent the reset of the exercise price of certain March 2025 warrants to purchase 957,200 shares of common stock from $1.00 to $0.67 per share.
[4]	Warrants represent the reset of the exercise price of certain March 2025 warrants to purchase 2,105,265 shares of common stock from $1.00 to $0.67 per share.

Schedule of Information Related to Stock Warrants

The following table presents information related to stock warrants as of December 31, 2025:

Warrants Outstanding				Warrants Exercisable
		Outstanding		Weighted Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Warrants		In Years		Warrants
$	0.67		6,124,930		4.52		6,124,930
$	2.06		679,800		4.44		679,800
$	12.50		4,050		2.94		4,050
$	47.50		20,347		3.20		20,347
$	57.75		19,965		2.52		19,965
$	350.00		27,551		2.32		27,551
$	700.00		13,944		1.95		13,944
$	1,760.50		200		-		-
$	2,415.00		3,651		1.95		3,651
$	4,025.00		17,335		1.95		17,335
			6,911,773		4.48		6,911,573

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Schedule of Issuance Date Fair Value of Stock Warrants

The modification date fair value of stock warrants modified during the years ended December 31, 2025 and 2024 was determined using the Black Scholes method, with the following assumptions used:

	For the Years Ended
	December 31,
	2025			2024
Fair value of common stock on date of modification		$0.64 - $0.98			$2.54 - $3.46
Risk free interest rate		3.92% - 4.09	%		3.62% - 4.62	%
Expected term (years)		4.9 - 5.3 years			0.6 - 5.3 years
Expected volatility		125	%		87% - 111	%
Expected dividends		n/a			n/a

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

+ Details

In-Process Research and Development (Details Narrative) $ in Millions	12 Months Ended
	Dec. 31, 2025 USD ($)
Research and Development [Abstract]
Impairment charges	$ 18.6

Schedule of Issuance Date Fair Value of Stock Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Minimum [Member]
Risk free interest rate	3.55%
Expected term (years)	2 months 26 days
Expected volatility	78.70%
Minimum [Member] \| Warrant [Member]
Fair value of common stock on date of grant	$ 0.64	$ 2.54
Risk free interest rate	3.92%	3.62%
Expected term (years)	4 years 10 months 24 days	7 months 6 days
Expected volatility		87.00%
Maximum [Member]
Risk free interest rate	4.09%
Expected term (years)	9 years 9 months
Expected volatility	161.50%
Maximum [Member] \| Warrant [Member]
Fair value of common stock on date of grant	$ 0.98	$ 3.46
Risk free interest rate	4.09%	4.62%
Expected term (years)	5 years 3 months 18 days	5 years 3 months 18 days
Expected volatility	125.00%	111.00%

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 14,419,237	$ 12,544,318
Stock-based compensation	3,099,252	3,155,058
Capitalized research and development costs	1,360,579	1,753,207
Capitalized start-up costs	650,957	781,342
Capitalized licensing costs	563,812	609,669
Capitalized patents	443,841	392,691
Warrants	135,527	135,319
Accrued Payroll	618,058	394,406
Contributions carryforward	125	2,878
Deferred tax asset	21,291,388	19,768,888
Valuation Allowance	(21,291,388)	(15,953,288)
Deferred tax assets		3,815,600
IPR&D		(4,667,259)
Deferred tax liability		(4,667,259)
Net deferred tax liability		$ (851,659)

Schedule of Stock Options Granted (Details)	12 Months Ended
Schedule of Stock Options Granted (Details)	Dec. 31, 2025 $ / shares
Expected dividends	0.00%
Minimum [Member]
Fair value of common stock on date of grant	$ 0.13
Risk free interest rate	3.55%
Expected term (years)	2 months 26 days
Expected volatility	78.70%
Maximum [Member]
Fair value of common stock on date of grant	$ 0.59
Risk free interest rate	4.09%
Expected term (years)	9 years 9 months
Expected volatility	161.50%

Schedule of Cash Paid for Income Taxes (Details)	12 Months Ended
Schedule of Cash Paid for Income Taxes (Details)	Dec. 31, 2025 USD ($)
Income Tax Disclosure [Abstract]
Federal
State and Local
Total Income Taxes Paid, Net

Schedule of Valuation Allowance (Details)	12 Months Ended
Schedule of Valuation Allowance (Details)	Dec. 31, 2025 USD ($)
Income Tax Disclosure [Abstract]
Valuation Allowance - beginning of period	$ (15,953,288)
Additions charged to income tax benefit
Allowances taken or written off	(5,338,100)
Other adjustments
Valuation allowance - end of period	$ (21,291,388)

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Our use of information systems for using, transmitting and storing data is a vital aspect of our business operations. Information systems can be vulnerable to a range of cybersecurity threats that could potentially have a material impact on our business strategy, results of operations and financial condition. Cybersecurity is a key category within our risk management efforts, and our cybersecurity risk management is intended to assist in assessing, identifying, and managing material risks from cybersecurity threats to the Company’s information systems. Our cybersecurity risk management and strategy is based upon utilizing systems that are cloud based which require multifactor authentication to access. Due to our small size, we partner with a third-party service provider which utilizes multiple security operations centers. The security operations centers maintain, monitor, mitigate and alert on threats against the cloud systems that we utilize. If a risk is identified the security operations center has the ability to shut down access to any user in the organization. The Audit Committee of our Board of Directors is responsible for oversight of the Company’s cyber-risk management and management’s role is to assist the Audit Committee in identifying and considering material cybersecurity risks, ensure implementation of management and employee level cybersecurity practices and training and provide the Audit Committee with unrestricted access to Company personnel and documents regarding any cybersecurity attacks or vulnerabilities. We also require our employees to participate in cybersecurity training and awareness programs. Company’s employees are expected to help safeguard the Company’s information systems and to assist in the discovery and reporting of cybersecurity incidents. These programs are intended to decrease cybersecurity risks associated with human error and foster a culture of cybersecurity consciousness. To date, the risks from cybersecurity threats, including as a result of any previous immaterial cybersecurity incidents, have not materially affected, or are reasonably likely to materially affect our business strategy, results of operations, or financial condition. While our insurance covers certain cybersecurity related matters, the costs related to cybersecurity threats or disruptions may not be fully insured.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	The Audit Committee of our Board of Directors is responsible for oversight of the Company’s cyber-risk management and management’s role is to assist the Audit Committee in identifying and considering material cybersecurity risks, ensure implementation of management and employee level cybersecurity practices and training and provide the Audit Committee with unrestricted access to Company personnel and documents regarding any cybersecurity attacks or vulnerabilities.

Schedule of Income (loss) Before Provision for Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Domestic	$ (25,804,037)	$ (9,406,690)
Foreign
Pre-Tax Net Loss	$ (25,804,037)	$ (9,406,690)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Schedule of Stock Option Activity (Details)	12 Months Ended
Schedule of Stock Option Activity (Details)	Dec. 31, 2025 USD ($) $ / shares shares
Equity [Abstract]
Number of Options, Outstanding beginning balance \| shares	9,612
Weighted Average Exercise Price, Outstanding beginning balance \| $ / shares	$ 2,248.58
Number of Options, Granted \| shares	377,964
Weighted Average Exercise Price, Granted \| $ / shares	$ 0.59
Number of Options, Exercised \| shares
Weighted Average Exercise Price, Exercised \| $ / shares
Number of Options, Expired \| shares	(219)
Weighted Average Exercise Price, Expired \| $ / shares	$ 1,760.50
Number of Options, Outstanding ending balance \| shares	387,357
Weighted Average Exercise Price, Outstanding ending balance \| $ / shares	$ 55.67
Weighted Average Remaining Life in years, Outstanding	9 years 4 months 24 days
Aggregate Intrinsic Value, Outstanding \| $
Number of Options, Exercisable \| shares	8,045
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 2,605.21
Weighted Average Remaining Life in years, Exercisable	5 years 1 month 6 days
Aggregate Intrinsic Value, Exercisable \| $

Schedule of Information Related to Stock Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants, outstanding	6,911,773	1,747,093
Options exercisable, Number of options	6,911,573
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants, outstanding	6,911,773
Warrant exercisable, weighted average remaining life in years	4 years 5 months 23 days
Options exercisable, Number of options	6,911,573
Exercise Price One [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 0.67
Number of warrants, outstanding	6,124,930
Warrant exercisable, weighted average remaining life in years	4 years 6 months 7 days
Options exercisable, Number of options	6,124,930
Exercise Price Two [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 2.06
Number of warrants, outstanding	679,800
Warrant exercisable, weighted average remaining life in years	4 years 5 months 8 days
Options exercisable, Number of options	679,800
Exercise Price Three [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 12.50
Number of warrants, outstanding	4,050
Warrant exercisable, weighted average remaining life in years	2 years 11 months 8 days
Options exercisable, Number of options	4,050
Exercise Price Four [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 47.50
Number of warrants, outstanding	20,347
Warrant exercisable, weighted average remaining life in years	3 years 2 months 12 days
Options exercisable, Number of options	20,347
Exercise Price Five [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 57.75
Number of warrants, outstanding	19,965
Warrant exercisable, weighted average remaining life in years	2 years 6 months 7 days
Options exercisable, Number of options	19,965
Exercise Price Six [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 350.00
Number of warrants, outstanding	27,551
Warrant exercisable, weighted average remaining life in years	2 years 3 months 25 days
Options exercisable, Number of options	27,551
Exercise Price Seven [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 700.00
Number of warrants, outstanding	13,944
Warrant exercisable, weighted average remaining life in years	1 year 11 months 12 days
Options exercisable, Number of options	13,944
Exercise Price Eight [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 1,760.50
Number of warrants, outstanding	200
Exercise Price Nine [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 2,415.00
Number of warrants, outstanding	3,651
Warrant exercisable, weighted average remaining life in years	1 year 11 months 12 days
Options exercisable, Number of options	3,651
Exercise Price Ten [Member] \| Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average exercise price, outstanding	$ 4,025.00
Number of warrants, outstanding	17,335
Warrant exercisable, weighted average remaining life in years	1 year 11 months 12 days
Options exercisable, Number of options	17,335

Summary of Significant Accounting Policies (Details Narrative)		12 Months Ended
	Apr. 25, 2024	Dec. 31, 2025 USD ($) Segment	Dec. 31, 2024 USD ($)
Product Information [Line Items]
Reverse stock split	the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock
Cash equivalents		$ 0	$ 0
Estimated useful life		5 years
Equipment		$ 52,000	52,000
Accumulated depreciation		52,000	52,000
Depreciation of fixed assets			$ 6,933
Number of operating segment \| Segment		1
Number of reportable segment \| Segment		1
Accounts Payable [Member] \| Customer Concentration Risk [Member] \| One Vendor Accounted [Member]
Product Information [Line Items]
Concentration risk percentage		56.00%	56.00%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Schedule of Income (loss) Before Provision for Income Taxes

Our income (loss) before provision for income taxes for the years ended December 31, 2025 and 2024 was as follows:

	12/31/2025			12/31/2024
Domestic	$	(25,804,037	)	$	(9,406,690	)
Foreign		-			-
Income before income taxes	$	(25,804,037	)	$	(9,406,690	)

Schedule of Provision for Income Taxes

The components of income (loss) before provision for income taxes are as follows for the years ended December 31, 2025 and 2024:

Schedule of Provision for Income Taxes

	2025			2024
	For the Years Ended
	December 31,
	2025			2024

Current tax benefit:
Federal	$	-		$	-
State		-			23,240
Current tax benefit		-			23,240

Deferred tax benefit:
Federal		(5,062,687	)		(1,688,265	)
State		(1,127,073	)		(164,376	)
Deferred tax benefit		(6,189,760	)		(1,852,641	)
Change in valuation allowance		5,338,101			1,859,386
Provision for income taxes	$	(851,659	)	$	6,745

Schedule of Provision for Benefit from Income Taxes Federal Statutory Rate

The reconciliation of taxes at the federal statutory rate to our provision for (benefit from) income taxes for the year ended December 31, 2025 in accordance with the guidance upon adoption of ASU 2023-09 was as follows:

Description	Amount			Percent
	For the Year Ended
	December 31, 2025
Description	Amount			Percent
U.S. Federal Statutory Tax Rate		(5,418,848	)		21.0	%
State Income Taxes, Net of Federal Income Tax Effect ^[1]		99,730			-0.4	%
Permanent items
Stock Based Comp
Effect of change in state rate
Prior period adjustments and other
Valuation Allowance		4,297,670			-16.7	%
Nontaxable or Nondeductible items		126,650			-0.4	%
Other		43,139			-0.2	%
Effective Tax Rate		(851,659	)		3.3	%

[1]	State taxes in Florida made up the majority (greater than 50 percent) of the tax effect in this category.

The reconciliation of taxes at the federal statutory rate to our provision for (benefit from) income taxes for the year ended December 31, 2024 in accordance with the guidance prior to the adoption of ASU 2023-09 was as follows:

	For the Year Ended
	December 31, 2024
Federal statutory rate		21.0	%
State tax rate, net of federal benefit		3.0	%
Permanent items		(0.0	)%
Stock Based Comp		(3.2	)%
Effect of change in state rate		0.2	%
Prior period adjustments and other		(1.3	)%
Change in valuation allowance		(19.8	)%
Other		0.0	%
Effective income tax rate		(0.1	)%

Schedule of Deferred Tax Assets and Liabilities

The cumulative tax effect of significant items comprising our net deferred tax asset (liability) is as follows for December 31, 2025 and 2024:

Deferred tax asset attributable to:	2025			2024
	As of
	December 31,
Deferred tax asset attributable to:	2025			2024
Net operating loss carryforwards	$	14,419,237		$	12,544,318
Stock-based compensation		3,099,252			3,155,058
Capitalized research and development costs		1,360,579			1,753,207
Capitalized start-up costs		650,957			781,342
Capitalized licensing costs		563,812			609,669
Capitalized patents		443,841			392,691
Warrants		135,527			135,319
Accrued Payroll		618,058			394,406
Contributions carryforward		125			2,878
Deferred tax asset		21,291,388			19,768,888
Valuation Allowance		(21,291,388	)		(15,953,288	)
Deferred tax assets		-			3,815,600

IPR&D		-			(4,667,259	)

Deferred tax liability		-			(4,667,259	)

Net deferred tax liability	$	-		$	(851,659	)

Schedule of Valuation Allowance

Valuation Allowance	2025
Valuation Allowance - beginning of period	$	(15,953,288	)
Additions charged to income tax benefit		-
Allowances taken or written off		(5,338,100	)
Other adjustments		-
Valuation allowance - end of period	$	(21,291,388	)

Schedule of Cash Paid for Income Taxes

Upon adoption of ASU 2023-09, Improvements to Income Tax Disclosures, as described in Note 2, Summary of Significant Accounting Policies, cash paid for income taxes, net of refunds, during the year ended December 31, 2025 was as follows:

Schedule of Cash Paid for Income Taxes

Income Tax Paid	2025
Federal	$	-
State and Local		-

Total Income Taxes Paid, Net	$	-

Commitments and Contingencies (Details Narrative)						12 Months Ended
Commitments and Contingencies (Details Narrative)	Jan. 09, 2025 USD ($)	Jul. 01, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jan. 15, 2024 USD ($)	Jan. 18, 2019 USD ($) ft²	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Invoices from a vendor		$ 144,300	$ 923,880
Accrued interest						$ 2,611,296	$ 1,894,041
Unaccrued interest						1,066,978	1,066,978
Number of operating lease square feet \| ft²					3,500
Lease cost					$ 89,000
Operating lease rent expense					$ 497,000	175,660	170,022
Lease Commitment [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Operating lease rent expense	$ 120,819			$ 112,064
Accrued Expenses and Other Current Liabilities [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Accrued interest						$ 780,539	$ 268,972

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 7 – Commitments and Contingencies

Litigations, Claims and Assessments

The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records contingent liabilities resulting from such claims, if any, when a loss is assessed to be probable and the amount of the loss is reasonably estimable.

Disputed Vendor Invoices

On June 30, 2024 and July 1, 2024, the Company received two invoices from a vendor in the amounts of $923,880 and $144,300, respectively. The June 30, 2024 invoice represents retroactive interest on invoices going back to September 30, 2022. The July 1, 2024 invoice included miscellaneous unsupported charges related to services performed over the past several years. On August 1, 2024, ZyVersa management sent the vendor a letter disputing the interest and unsupported charges and has requested the vendor to rescind each of them. Although the Company has requested the vendor to rescind the retroactive interest on invoices, the Company believes that, in accordance with the agreement, the vendor can legally charge the Company interest from the point they were notified of the vendor’s intent to charge interest. As such, the Company began accruing interest starting on July 1, 2024, and accordingly, has recorded $780,539 and $268,972 within accrued expenses and other current liabilities on the consolidated balance sheets as of December 31, 2025 and 2024, respectively. The Company has accounted for the unaccrued interest and unsupported charges of $1,066,978 as a loss contingency and because the liability is not deemed probable, it has not been recorded as a liability in the consolidated balance sheet as of December 31, 2025 or 2024.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Operating Leases

On January 18, 2019, the Company entered into a lease agreement for approximately 3,500 square feet of office space in Weston, Florida for a term of five years. Under the lease agreement, the annual base rent, which excludes the Company’s share of taxes and operating costs, was approximately $89,000 for the first year and has increased approximately 3% every year thereafter for a total base rent lease commitment of approximately $497,000. On January 15, 2024, the Company extended the lease for an additional year for a total base rent lease commitment of $112,064. On January 9, 2025, the Company extended the lease for an additional year for a total base rent lease commitment of approximately $120,819. The Company used the short-term lease practical expedient which permits the Company to not capitalize leases with a term equal to or less than 12 months. The lease agreement ended on January 31, 2026 and it was not extended.

The Company recognized rent expense in connection with its operating lease for the years ended December 31, 2025 and 2024 of $175,660 and $170,022, respectively.

Summary of Warrant Activity (Details)	12 Months Ended
Summary of Warrant Activity (Details)	Dec. 31, 2025 USD ($) $ / shares shares
Equity [Abstract]
Number of warrants, outstanding beginning balance \| shares	1,747,093
Weighted average exercise price, beginning balance \| $ / shares	$ 59.59
Number of warrants, Issued \| shares	8,230,195
Weighted average exercise price, Issued \| $ / shares	$ 0.75
Number of warrants, repriced - old two \| shares	(957,200)
Weighted average exercise price, repriced - old two \| $ / shares	$ 2.06
Number of warrants, repriced - new two \| shares	957,200
Weighted average exercise price, repriced - new two \| $ / shares	$ 1.00
Number of warrants, repriced - old three \| shares	(957,200)
Weighted average exercise price, repriced - old three \| $ / shares	$ 1.00
Number of warrants, repriced - new three \| shares	957,200
Weighted average exercise price, repriced - new three \| $ / shares	$ 0.67
Number of warrants, repriced - old four \| shares	(2,105,265)
Weighted average exercise price, repriced - old four \| $ / shares	$ 1.00
Number of warrants, repriced - new four \| shares	2,105,265
Weighted average exercise price, repriced - new four \| $ / shares	$ 0.67
Number of warrants, forfeited \| shares	(3,050)
Weighted average exercise price, forfeited \| $ / shares	$ 12.50
Number of warrants, exercised \| shares	(3,062,465)
Weighted average exercise price, exercised \| $ / shares	$ 0.67
Number of warrants, outstanding ending balance \| shares	6,911,773
Weighted average exercise price, ending balance \| $ / shares	$ 15.34
Weighted average remaining life in years, outstanding	4 years 5 months 23 days
Aggregate intrinsic value, ending balance \| $
Number of warrants, exercisable ending balance \| shares	6,911,573
Weighted average exercise price, Exercisable \| $ / shares	$ 15.29
Weighted average remaining life in years, exercisable	4 years 5 months 23 days
Aggregate intrinsic value, exercisable \| $

Income Taxes

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Income Taxes

Note 6 – Income Taxes

The Company is subject to United States federal and state income taxes.

Our income (loss) before provision for income taxes for the years ended December 31, 2025 and 2024 was as follows:

	12/31/2025			12/31/2024
Domestic	$	(25,804,037	)	$	(9,406,690	)
Foreign		-			-
Income before income taxes	$	(25,804,037	)	$	(9,406,690	)

The components of income (loss) before provision for income taxes are as follows for the years ended December 31, 2025 and 2024:

Schedule of Provision for Income Taxes

	2025			2024
	For the Years Ended
	December 31,
	2025			2024

Current tax benefit:
Federal	$	-		$	-
State		-			23,240
Current tax benefit		-			23,240

Deferred tax benefit:
Federal		(5,062,687	)		(1,688,265	)
State		(1,127,073	)		(164,376	)
Deferred tax benefit		(6,189,760	)		(1,852,641	)
Change in valuation allowance		5,338,101			1,859,386
Provision for income taxes	$	(851,659	)	$	6,745

Description	Amount			Percent
	For the Year Ended
	December 31, 2025
Description	Amount			Percent
U.S. Federal Statutory Tax Rate		(5,418,848	)		21.0	%
State Income Taxes, Net of Federal Income Tax Effect ^[1]		99,730			-0.4	%
Permanent items
Stock Based Comp
Effect of change in state rate
Prior period adjustments and other
Valuation Allowance		4,297,670			-16.7	%
Nontaxable or Nondeductible items		126,650			-0.4	%
Other		43,139			-0.2	%
Effective Tax Rate		(851,659	)		3.3	%

[1]	State taxes in Florida made up the majority (greater than 50 percent) of the tax effect in this category.

	For the Year Ended
	December 31, 2024
Federal statutory rate		21.0	%
State tax rate, net of federal benefit		3.0	%
Permanent items		(0.0	)%
Stock Based Comp		(3.2	)%
Effect of change in state rate		0.2	%
Prior period adjustments and other		(1.3	)%
Change in valuation allowance		(19.8	)%
Other		0.0	%
Effective income tax rate		(0.1	)%

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The cumulative tax effect of significant items comprising our net deferred tax asset (liability) is as follows for December 31, 2025 and 2024:

Deferred tax asset attributable to:	2025			2024
	As of
	December 31,
Deferred tax asset attributable to:	2025			2024
Net operating loss carryforwards	$	14,419,237		$	12,544,318
Stock-based compensation		3,099,252			3,155,058
Capitalized research and development costs		1,360,579			1,753,207
Capitalized start-up costs		650,957			781,342
Capitalized licensing costs		563,812			609,669
Capitalized patents		443,841			392,691
Warrants		135,527			135,319
Accrued Payroll		618,058			394,406
Contributions carryforward		125			2,878
Deferred tax asset		21,291,388			19,768,888
Valuation Allowance		(21,291,388	)		(15,953,288	)
Deferred tax assets		-			3,815,600

IPR&D		-			(4,667,259	)

Deferred tax liability		-			(4,667,259	)

Net deferred tax liability	$	-		$	(851,659	)

As of December 31, 2025, the Company has federal net operating loss carryforwards totaling $59,859,961. All federal NOLs were generated in tax years beginning after December 31, 2017, and may be carried forward indefinitely. Utilization of these NOLs is limited to offsetting up to 80% of taxable income in any given year, in accordance with the Tax Cuts and Jobs Act. The NOL carryforwards are subject to limitations under Section 382 of the Internal Revenue Code in the event of a change in ownership.

The Company has state net operating loss carryforwards totaling $42,546,493 as of December 31, 2025. All NOLs were generated in tax years beginning after December 31, 2017, and may be carried forward indefinitely, subject to annual deduction limitations under state tax law.

A valuation allowance of $21,291,388 has been recorded against deferred tax assets, including carryforwards, where it is not more likely than not that such assets will be realized. The Company evaluates the realizability of carryforwards based on projections of future taxable income and other relevant factors.

Schedule of Valuation Allowance

Valuation Allowance	2025
Valuation Allowance - beginning of period	$	(15,953,288	)
Additions charged to income tax benefit		-
Allowances taken or written off		(5,338,100	)
Other adjustments		-
Valuation allowance - end of period	$	(21,291,388	)

Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2025 and 2024.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

No tax audits were commenced or were in process during the years ended December 31, 2025 and 2024 and no tax-related interest or penalties were incurred during those years. The Company’s tax returns beginning with the year ended December 31, 2021 remain subject to examination.

Schedule of Cash Paid for Income Taxes

Income Tax Paid	2025
Federal	$	-
State and Local		-

Total Income Taxes Paid, Net	$	-

Tax Law Change

On July 4th, 2025, the President signed into law significant federal tax legislation, H.R.1 (the “Tax Reform Act of 2025”). The legislation includes numerous changes to U.S. corporate income tax law, including but not limited to: permanent 100% bonus depreciation for qualified property, immediate expensing of domestic research and experimental expenditures, modifications to the limitation on business interest expense, increased Section 179 expensing limits, changes to the international tax regime, and expanded limitations on the deductibility of executive compensation under IRC Section 162(m). Most provisions are effective for tax years beginning after December 31, 2024, with certain transition rules and exceptions.

The Company has evaluated the impact of the Tax Reform Act of 2025 on its consolidated financial statements. There was no material impact given the Company’s tax loss profile and valuation allowance position.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Cover - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
Cover - USD ($) $ / shares in Units, $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Mar. 25, 2026	Jun. 30, 2025
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2025
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--12-31
Entity File Number	001-41184
Entity Registrant Name	ZYVERSA THERAPEUTICS, INC.
Entity Central Index Key	0001859007
Entity Tax Identification Number	86-2685744
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2436 N. Federal Highway
Entity Address, Address Line Two	Suite 466
Entity Address, City or Town	Lighthouse Point
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33064
City Area Code	(754)
Local Phone Number	231-1688
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ZVSA
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float				$ 3.3
Entity Common Stock, Shares Outstanding			8,095,921
Document Financial Statement Error Correction [Flag]	false
Entity Listing, Par Value Per Share	$ 0.0001
Auditor Firm ID	199	688
Auditor Opinion [Text Block]	We have audited the accompanying consolidated balance sheet of ZyVersa Therapeutics, Inc. (the “Company”) as of December 31, 2025 the related consolidated statements of operations, changes in stockholders’ deficit, and cash flows for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, based on our audit, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.
Auditor Name	CBIZ CPAs P.C.	Marcum LLP
Auditor Location	New York, NY	New York, NY

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	Feb. 27, 2026	Dec. 31, 2025	Dec. 31, 2024
Subsequent Event [Line Items]
common stock par value		$ 0.0001	$ 0.0001
Subsequent Event [Member]
Subsequent Event [Line Items]
Aggregate principal amount	$ 1.0
common stock par value	$ 0.0001
Interest rate	10.00%
Debt maturity date, description	The Notes mature twelve months from the date of issuance and are convertible into shares of Common Stock at a conversion price equal to (i) 80% of the price per share paid in a Qualified Offering, upon its occurrence, or (ii) 80% of the lowest daily volume-weighted average price of the Common Stock during the 10 trading days prior to delivery of a conversion notice that occurs following the earlier of (x) six months after the issuance date or (y) an event of default
Share price subject to floor price, per share	$ 0.02
Warrant exercise price, description	The exercise price of the Warrants is equal to (i) 110% of the price per share paid in a Qualified Offering that occurs by the Initial Exercise Date, or (ii) 110% of the volume-weighted average price for the five-trading-day period beginning on the 181st day and ending on the 185th day after the issuance date if a Qualified Offering has not occurred by the Initial Exercise Date. The number of shares of Common Stock issuable upon exercise of each Warrant is calculated by dividing 50% of the applicable Purchaser’s subscription amount by the exercise price

Segment Reporting

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Segment Reporting

Note 9 – Segment Reporting

The Company has one operating and reporting segment (clinical stage biopharmaceutical), namely, the development of drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The chief operating decision maker (“CODM”), who is the Company’s chief executive officer, utilizes the Company’s financial information on an aggregate, consolidated basis for purposes of making operating decisions, allocating resources and assessing financial performance, as well as for making strategic operations decisions and managing the organization. The CODM is not regularly provided with disaggregated actual expense information, other than the actual expense information included in the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The Company has not yet generated any revenue from product sales.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following as of December 31, 2025 and December 31, 2024:

	2025		2024
	For the Years Ended
	December 31,
	2025		2024

Payroll accrual	$	1,343,382	$	1,039,338
Interest accrual		666,958		268,972
Bonus accrual		536,500		536,500
Accrued issuable equity		57,195		-
Other accrued expenses		-		41,970
Registration delay liability		7,261		7,261
Total accrued expenses and other current liabilities	$	2,611,296	$	1,894,041

Schedule of Information Related to Stock Options (Details)	12 Months Ended
	Dec. 31, 2025 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	387,357
Options Exercisable, Number of options	8,045
Options Exercisable, Weighted Average Remaining Life in Years	5 years 1 month 6 days
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 0.59
Options Outstanding, Number of Options	377,964
Options Exercisable, Number of options
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 152.50
Options Outstanding, Number of Options	4,157
Options Exercisable, Number of options	2,916
Options Exercisable, Weighted Average Remaining Life in Years	7 years 4 months 24 days
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 738.50
Options Outstanding, Number of Options	286
Options Exercisable, Number of options	191
Options Exercisable, Weighted Average Remaining Life in Years	7 years 1 month 6 days
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 791.00
Options Outstanding, Number of Options	38
Options Exercisable, Number of options	26
Options Exercisable, Weighted Average Remaining Life in Years	7 years 2 months 12 days
Exercise Price Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 1,760.50
Options Outstanding, Number of Options	1,060
Options Exercisable, Number of options	1,060
Options Exercisable, Weighted Average Remaining Life in Years	1 year 2 months 12 days
Exercise Price Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 3,965.50
Options Outstanding, Number of Options	37
Options Exercisable, Number of options	37
Options Exercisable, Weighted Average Remaining Life in Years	6 years 6 months
Exercise Price Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 4,053.00
Options Outstanding, Number of Options	2,095
Options Exercisable, Number of options	2,095
Options Exercisable, Weighted Average Remaining Life in Years	3 years 3 months 18 days
Exercise Price Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 5,726.00
Options Outstanding, Number of Options	1,720
Options Exercisable, Number of options	1,720
Options Exercisable, Weighted Average Remaining Life in Years	5 years 6 months

Summary of Warrant Activity (Details) (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2025	Jul. 08, 2025
Class of Warrant or Right [Line Items]
Number of warrants, outstanding	387,357
Warrants exercise price		$ 1.00
Number of warrants, exercised	3,062,465
March 2025 PreFunded Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants, outstanding	2,105,265
Warrants exercise price	$ 0.0001
November 2024 Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants, exercised	957,200
November 2024 Warrants [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants per share	$ 2.06
November 2024 Warrants [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants per share	$ 1.00
March 2025 Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants, exercised	957,200
March 2025 Warrants [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants per share	$ 1.00
March 2025 Warrants [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants per share	$ 0.67
March 2025 Warrants One [Member]
Class of Warrant or Right [Line Items]
Number of warrants, exercised	2,105,265
March 2025 Warrants One [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants per share	$ 1.00
March 2025 Warrants One [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Purchase of warrants per share	$ 0.67

Subsequent Events

12 Months Ended

Dec. 31, 2025

Subsequent Events [Abstract]

Subsequent Events

Note 10 – Subsequent Events

The Company has evaluated subsequent events through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as discussed below.

Securities Purchase Agreement

On February 27, 2026, the Company entered into a Securities Purchase Agreement with certain accredited investors, pursuant to which the Company issued convertible promissory notes (the “Notes”) in an aggregate principal amount of $1.0 million and Series A-4 Common Stock Purchase Warrants (the “Warrants”) to purchase shares of the Company’s common stock, par value $0.0001 per share.

The Notes bear interest at a rate of 10% per annum, with interest accruing on the unpaid principal amount and payable on the maturity date. The Notes mature twelve months from the date of issuance and are convertible into shares of Common Stock at a conversion price equal to (i) 80% of the price per share paid in a Qualified Offering, upon its occurrence, or (ii) 80% of the lowest daily volume-weighted average price of the Common Stock during the 10 trading days prior to delivery of a conversion notice that occurs following the earlier of (x) six months after the issuance date or (y) an event of default. This share price is subject to a floor price of $0.02 per share.

The Warrants are exercisable beginning on the six-month anniversary of their issuance (the “Initial Exercise Date”), and expire on the five-year anniversary of the issuance date. The exercise price of the Warrants is equal to (i) 110% of the price per share paid in a Qualified Offering that occurs by the Initial Exercise Date, or (ii) 110% of the volume-weighted average price for the five-trading-day period beginning on the 181st day and ending on the 185th day after the issuance date if a Qualified Offering has not occurred by the Initial Exercise Date. The number of shares of Common Stock issuable upon exercise of each Warrant is calculated by dividing 50% of the applicable Purchaser’s subscription amount by the exercise price. The Warrants contain standard anti-dilution adjustments, including adjustments for stock dividends, stock splits, and certain fundamental transactions.

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Payables and Accruals [Abstract]
Payroll accrual	$ 1,343,382	$ 1,039,338
Interest accrual	666,958	268,972
Bonus accrual	536,500	536,500
Accrued issuable equity	57,195
Other accrued expenses		41,970
Registration delay liability	7,261	7,261
Total accrued expenses and other current liabilities	$ 2,611,296	$ 1,894,041

- Definition

Amount of liabilities classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 64
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481620/480-10-55-64

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(12)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(12)(b)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(12)(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Going Concern and Management’s Plans

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern and Management’s Plans

Note 2 - Going Concern and Management’s Plans

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

As of December 31, 2025, the Company had cash of approximately $0.1 million and a working capital deficit of approximately $12.4 million. During the year ended December 31, 2025, the Company incurred a net loss of approximately $25.0 million and used cash in operations of approximately $5.1 million. The Company has an accumulated deficit of approximately $137.6 million as of December 31, 2025.

The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.

Consequently, the Company will be required to raise additional funds through equity or debt financing. On February 27, 2026, the Company entered into a Securities Purchase agreement and received approximately $1.0 million. See Note 10 – Subsequent Events – Securities Purchase Agreement for additional details. Management believes that the Company has access to capital resources and continues to evaluate additional financing opportunities; however, there can be no assurance that it will be successful in securing additional capital or that the Company will be able to obtain funds on commercially acceptable terms, if at all. There is also no assurance that the amount of funds the Company might raise will enable the Company to complete its development initiatives or attain profitable operations. The aforementioned conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance date of these financial statements.

Consolidated Balance Sheets - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Current Assets:
Cash	$ 101,778	$ 1,530,924
Prepaid expenses and other current assets	231,639	184,873
Vendor deposits	14,484
Total Current Assets	347,901	1,715,797
In-process research and development		18,647,903
Vendor deposit		178,476
Deferred offering costs		57,238
Total Assets	347,901	20,599,414
Current Liabilities:
Accounts payable	10,123,391	9,337,267
Accrued expenses and other current liabilities	2,611,296	1,894,041
Total Current Liabilities	12,734,687	11,231,308
Deferred tax liability		851,659
Total Liabilities	12,734,687	12,082,967
Commitments and contingencies (Note 6)
Stockholders’ (Deficit) Equity:
Common stock	809	251
Additional paid-in-capital	125,204,509	121,155,922
Accumulated deficit	(137,584,937)	(112,632,559)
Treasury stock, at cost, 7 shares at December 31, 2025 and 2024	(7,168)	(7,168)
Total Stockholders’ (Deficit) Equity	(12,386,786)	8,516,447
Total Liabilities and Stockholders’ (Deficit) Equity	347,901	20,599,414
Series A Preferred Stock [Member]
Stockholders’ (Deficit) Equity:
Preferred stock
Series B Preferred Stock [Member]
Stockholders’ (Deficit) Equity:
Preferred stock	$ 1	$ 1

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Operating Expenses:
Research and development	$ 1,113,105	$ 1,779,275
General and administrative	5,731,682	7,357,559
Impairment of in-process research and development	18,647,903
Total Operating Expenses	25,492,690	9,136,834
Loss From Operations	(25,492,690)	(9,136,834)
Other (Income) Expense:
Interest expense	513,209	269,856
Change in fair value of equity payable	(201,862)
Pre-Tax Net Loss	(25,804,037)	(9,406,690)
Income tax benefit (provision)	851,659	(6,745)
Net Loss	$ (24,952,378)	$ (9,413,435)
Net Loss Per Share
Basic	$ (4.18)	$ (8.48)
Diluted	$ (4.18)	$ (8.48)
Weighted Average Number of Common Shares Outstanding
Basic	5,963,943	1,110,033
Diluted	5,963,943	1,110,033

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

Note 5 – Accrued Expenses and Other Current Liabilities‌

Accrued expenses and other current liabilities consisted of the following as of December 31, 2025 and December 31, 2024:

	2025		2024
	For the Years Ended
	December 31,
	2025		2024

Payroll accrual	$	1,343,382	$	1,039,338
Interest accrual		666,958		268,972
Bonus accrual		536,500		536,500
Accrued issuable equity		57,195		-
Other accrued expenses		-		41,970
Registration delay liability		7,261		7,261
Total accrued expenses and other current liabilities	$	2,611,296	$	1,894,041

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3 – Summary of Significant Accounting Policies‌

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been derived from the accounting records of the Company and its consolidated subsidiaries. All significant intercompany balances have been eliminated in the consolidated financial statements. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting rules and regulations of the United States Securities and Exchange Commission (“SEC”).

On April 25, 2024, the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock. In addition, the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants were proportionally decreased, and the corresponding conversion price or exercise price was proportionally increased. No fractional shares were issued as a result of the 2024 Reverse Split.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Accordingly, all share and per share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the 2024 Reverse Split and adjustment of the conversion price or exercise price of each outstanding equity award, convertible security and warrants as if the transaction had occurred as of the beginning of the earliest period presented.

Use of Estimates

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, share based compensation, impairment of in-process research and development, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of December 31, 2025 and 2024, the Company had no cash equivalents.

The Company has cash deposits which, at times, may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions.

Business Combination

In applying the acquisition method of accounting for business combinations, amounts assigned to identifiable assets and liabilities acquired are based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Intangible assets are initially valued at fair value using generally accepted valuation methods appropriate for the type of intangible asset. In-process research and development (IPR&D) acquired in a business combination is capitalized as an indefinite-lived intangible asset until regulatory approval is obtained, at which time it is accounted for as a definite-lived asset and amortized over its estimated useful life, or discontinuation, at which point the intangible asset will be written off.

Long-Lived Assets

The Company accounts for long-lived assets in accordance with the provisions of ASC 360-10-35, Property, Plant and Equipment, Impairment or Disposal of Long-lived Assets. This accounting standard requires that definite-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.

Goodwill and Intangible Assets

The Company accounts for goodwill and intangible assets in accordance with ASC 350, Intangibles – Goodwill and Other. Goodwill represents the excess of the purchase price of an entity over the estimated fair value of the assets acquired and liabilities assumed. ASC 350 requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. The Company intends to perform its annual impairment testing during the fourth quarter of each year.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In determining whether a quantitative assessment is required, the Company evaluates relevant events or circumstances to determine whether it is more likely than not that the fair value of a reporting unit or an indefinite-lived intangible asset is less than its carrying amount. If, after performing the qualitative assessment, an entity concludes that it is more likely than not that the fair value of a reporting unit or an indefinite-lived intangible asset is less than its carrying amount, the entity would perform the quantitative impairment test described in ASC 350. However, if, after applying the qualitative assessment, the entity concludes that it is not more than likely that the fair value is less than the carrying amount, the quantitative impairment test is not required. The Company bases these assumptions on its historical data and experience, industry projections, micro and macro general economic condition projections, and its expectations.

Equipment, Net

Equipment is stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date and depreciated using the straight- line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which is 5 years. As of December 31, 2025 and 2024, equipment consisted of $52,000 medical equipment, placed in service on September 1, 2019, less accumulated depreciation of $52,000 and $52,000 as of December 31, 2025 and 2024, respectively. During the years ended December 31, 2025 and 2024, the Company recognized depreciation expense of $0 and $6,933, respectively. Depreciation expense was included in general and administrative expenses in the statements of operations for the year ended December 31, 2024.

Deferred Offering Costs

Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with a debt or equity financing, are capitalized as deferred offering costs (a non-current asset) on the balance sheet. Once the financing closes, the Company reclassifies such costs as either discounts to notes payable or as a reduction of proceeds received from equity transactions so that such costs are recorded as a reduction of additional paid-in capital. If the completion of a contemplated financing was deemed to be no longer probable, the related deferred offering costs would be charged to general and administrative expense in the consolidated financial statements.

Fair Value of Financial Instruments

The Company measures the fair value of financial assets and liabilities based on ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities;

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and

Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

The carrying amounts of the Company’s financial instruments, such as cash, accounts payable, and deposits approximate fair values due to the short-term nature of these instruments.

Income Taxes

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

Research and Development

Research and development expenses are charged to operations as incurred.

Stock-Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

Warrant Classification

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

Fair Value of Stock Options and Warrants

The Company has computed the fair value of stock options and warrants granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. Common stock is being valued using the market approach using the trading prices of the common stock on the OTCQB® Venture Market. The expected term used for options is the estimated period of time that options granted are expected to be outstanding. The expected term used for warrants is the contractual life. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” option grants. The Company did not have a public trading history for the common shares to support its historical volatility calculations until December 13, 2022. Accordingly, the Company used a blended volatility whereby it uses its historical volatility for the period from December 13, 2022 through the valuation date and uses the average of peer-group data of four comparable entities to supplement its own historical data for the preceding years in computing its expected volatility. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of common and dilutive common-equivalent shares outstanding during each period.

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

	2025		2024
	For the Years Ended
	December 31,
	2025		2024
Warrants ^[1]		6,911,773		1,747,093
Options		387,357		9,612
Series A Convertible Preferred Stock		72		72
Series B Convertible Preferred Stock		2,067		2,067
Total potentially dilutive shares		7,301,269		1,758,844

[1]

As part of the InflamaCORE, LLC license agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported. See Note 8 - Commitments and Contingencies - License Agreements for details.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Vendor Concentration

As of December 31, 2025 and 2024, accounts payable to one vendor accounted for 56% of the accounts payable related to research and development. The Company relies on this vendor to perform critical research and development.

Segment Reporting

Reportable segments are components of an enterprise about which separate financial information is available for evaluation by the chief operating decision maker (“CODM”) in making decisions about how to allocate resources and assess performance. The Company has one operating and reporting segment (clinical stage biopharmaceutical), namely, the development of drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The CODM, who is the Company’s chief executive officer, utilizes the Company’s financial information on an aggregate, consolidated basis for purposes of making operating decisions, allocating resources and assessing financial performance, as well as for making strategic operations decisions and managing the organization. The CODM is not regularly provided with disaggregated actual expense information, other than the actual expense information included in the consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total assets. The Company has not yet generated any revenue from product sales.

Recently Issued Accounting Pronouncements

In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220 – 04). This update requires an entity to disclose more detailed information regarding expenses for the entity. The amendments require that at each interim and the annual reporting period, the entity must disclose amounts related to purchases of inventory, employee compensation, depreciation, and intangible asset amortization. Including the amounts, the entity is required to disclose and qualitative description of the amounts remaining in relevant expense captions, and to disclose the total amount of selling expenses and the definition of selling expenses. The amendments in this update should be applied prospectively to financial statements issued for reporting periods, and retrospectively to any prior periods presented in the financials. Although early adoption is permitted, the new guidance becomes effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Since this new ASU addresses only disclosures, the Company does not expect the adoption of this ASU to have any material effects on its financial condition, results of operations or cash flows.

Recently Adopted Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments in ASU 2023-09 were adopted by the Company on a prospective basis during the year ended December 31, 2025. There was no material impact to the Company’s financial statements as a result of adopting ASU 2023-09. Refer to Note 6 – Income Taxes for the inclusion of new disclosures required.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

	2025		2024
	For the Years Ended
	December 31,
	2025		2024
Warrants ^[1]		6,911,773		1,747,093
Options		387,357		9,612
Series A Convertible Preferred Stock		72		72
Series B Convertible Preferred Stock		2,067		2,067
Total potentially dilutive shares		7,301,269		1,758,844

[1]

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Net operating loss carry forwards, federal	$ 59,859,961
Net operating loss taxable income, description	Utilization of these NOLs is limited to offsetting up to 80% of taxable income in any given year, in accordance with the Tax Cuts and Jobs Act
Net operating loss carry forwards, state	$ 42,546,493
Valuation allowance	$ 21,291,388	$ 15,953,288

Schedule of Provision for Benefit from Income Taxes Federal Statutory Rate (Details) - USD ($)

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Federal statutory rate

21.00%

Federal statutory rate, amount

$ (5,418,848)

State tax rate, net of federal benefit

(0.40%)

^[1]

3.00%

State tax rate, net of federal benefit, amount

^[1]

$ 99,730

Permanent items

(0.00%)

Stock Based Comp

(3.20%)

Effect of change in state rate

0.20%

Prior period adjustments and other

(1.30%)

Change in valuation allowance

(16.70%)

(19.80%)

Change in valuation allowance, amount

$ 4,297,670

Nontaxable or Nondeductible items

(0.40%)

State and local income taxes net of federal tax benefit

$ 126,650

Other

(0.20%)

0.00%

Other, amount

$ 43,139

Effective income tax rate

3.30%

(0.10%)

Effective income tax rate, amount

$ (851,659)

$ 6,745

[1]	State taxes in Florida made up the majority (greater than 50 percent) of the tax effect in this category.

Business Organization and Nature of Operations

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Organization and Nature of Operations

Note 1 – Business Organization and Nature of Operations

Organization and Operations

ZyVersa Therapeutics, Inc. (“ZyVersa” and the “Company”) is a clinical stage biopharmaceutical company leveraging proprietary technologies to develop first-in-class drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The Company’s mission is to develop drugs that optimize health outcomes and improve patients’ quality of life.

Consolidated Statements of CashFlows - USD ($)	12 Months Ended
Consolidated Statements of CashFlows - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Cash Flows From Operating Activities:
Net loss	$ (24,952,378)	$ (9,413,435)
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment of in-process research and development	18,647,903
Stock-based compensation	222,831	705,567
Issuance of common stock pursuant to vendor agreements	240,000	196,770
Write-off of deferred offering costs	57,238
Depreciation of fixed assets		6,933
Non-cash rent expense		7,839
Deferred tax (benefit) provision	(851,659)	6,745
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(46,766)	30,586
Accounts payable	689,268	888,609
Vendor deposits	161,927	(80,000)
Operating lease liability		(8,656)
Accrued expenses and other current liabilities	717,255	139,508
Net Cash Used In Operating Activities	(5,114,381)	(7,519,534)
Cash Flows From Financing Activities:
Exercise of warrants		2,672,500
Private placement of warrants	1,999,791
Warrant inducement offer - exercise proceeds	2,051,852	2,514,088
Exercise of pre-funded warrants	210
Payment of offering costs		(40,163)
At the market issuance of stock proceeds		1,354,404
Registration and issuance costs associated with warrant issuance	(366,618)	(588,045)
Net Cash Provided By Financing Activities	3,685,235	5,912,784
Net Decrease in Cash	(1,429,146)	(1,606,750)
Cash - Beginning of Period	1,530,924	3,137,674
Cash - End of Period	101,778	1,530,924
Supplemental Disclosures of Cash Flow Information:
Interest
Income taxes
Non-cash investing and financing activities:
Warrant modifications - incremental value	1,816,646	3,033,284
Accounts payable and accrued expenses for offering costs	$ 98,921	$ 17,075

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical)	12 Months Ended
	Dec. 31, 2025 USD ($)
Gross proceeds
Cash issuance costs	290,317
Gross proceeds	1,999,791
Non cash warrant modification charges	53,890
Warrant [Member]
Gross proceeds	2,051,852
Cash issuance costs	175,222
Non cash warrant modification charges	$ 1,762,756

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2025	Dec. 31, 2024
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	8,095,928	2,508,198
Common stock, shares outstanding	8,095,921	2,508,191
Treasury stock, shares	7	7
Series A Preferred Stock [Member]
Preferred stock, shares authorized	8,635	8,635
Preferred stock, shares issued	50	50
Preferred stock, shares outstanding	50	50
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5,062	5,062
Preferred stock, shares issued	5,062	5,062
Preferred stock, shares outstanding	5,062	5,062

Schedule of Anti-dilutive Securities Excluded From Calculation of Diluted Net Loss Per Share (Details) (Parenthetical) - shares	Dec. 31, 2025	Dec. 31, 2024
InflamaCORE, LlC License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase common shares	342	342

Going Concern and Management’s Plans (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 101,778	$ 1,530,924
Working capital deficit	12,400,000
Net loss	24,952,378	9,413,435
Net cash used In operations	(5,114,381)	(7,519,534)
Accumulated deficit	$ 137,584,937	$ 112,632,559

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 45
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477796/946-210-45-21

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-SubTopic 210
-Topic 946
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477796/946-210-45-20

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

Stockholders’ Equity (Deficit)

12 Months Ended

Dec. 31, 2025

Equity [Abstract]

Stockholders’ Equity (Deficit)

Note 8 – Stockholders’ Equity (Deficit)

Equity Incentive Plans

Predecessor 2014 Equity Incentive Plan

On December 12, 2022, in connection with the consummation of the Business Combination, the Predecessor approved the amendment to the 2014 Plan (the “2014 Plan Amendment”). The 2014 Plan Amendment provides, among other things, that upon consummation of the Business Combination, no further increases in the shares of common stock reserved and available for issuance under the 2014 Plan shall occur and no new awards shall be made under the 2014 Plan.

2022 Omnibus Equity Incentive Plan

The Company is authorized to issue awards under the 2022 Omnibus Equity Incentive Plan (the “2022 Plan”), as amended on October 31, 2023 and October 29, 2024. Under the 2022 Plan, 382,122 shares of common stock are authorized for issuance as of December 31, 2025. The number of shares of common stock available for issuance under the 2022 Plan shall automatically increase on the first trading day of January each calendar year during the term of the 2022 Plan, beginning with calendar year 2023, by an amount equal to four percent (4%) of the total number of shares of common stock outstanding on the last trading day in December of the immediately preceding calendar year. The 2022 Plan provides for the issuance of incentive stock options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock units to employees, directors and consultants of the Company and its affiliates. The 2022 Plan requires the exercise price of stock options to be not less than the fair value of the Company’s common stock on the date of grant. As of December 31, 2025, there were 377,965 shares available for future issuance under the 2022 Plan.

On January 1, 2026, the total number of shares under the 2022 Omnibus Equity Incentive Plan automatically increased to 705,958.

Common Stock

On February 3, 2025, the Company entered into a marketing agreement with a vendor in which the Company agreed to issue 60,000 shares of common stock in exchange for marketing services. The fair value of the common stock of $81,600 was recognized as expense on a straight-line basis over the two-month term of the contract. The shares were issued on February 3, 2025.

On March 20, 2025, the Company entered into a marketing agreement with a vendor in which the Company agreed to issue 100,000 shares of common stock in exchange for digital marketing services. The fair value of the common stock of $70,100 was recognized as expense on a straight-line basis over the three-month term of the contract. On April 11, 2025, the Company issued the 100,000 shares of common stock to the vendor using the market value of $77,000 on that date. The difference between the original expense amount and the value when the shares were issued was reflected in the change in fair value of equity payable in other (income) expense on the condensed consolidated statements of operations.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

On May 1, 2025, the Company entered into a marketing agreement with a vendor in which the Company agreed to issue 100,000 shares of common stock in exchange for marketing services. The fair value of the common stock of $51,800 was recognized as expense on a straight-line basis of the expense over the two-month term of the contract. On May 13, 2025, the Company issued the 100,000 shares of common stock to the vendor using the market value of $51,800 on that date.

On August 1, 2025, the Company entered into a marketing agreement with a vendor in which the Company agreed to issue 160,000 shares of common stock in exchange for marketing services. The fair value of the common stock of $29,600 was recognized as expense on a straight-line basis over the two-month term of the contract.

Equity Purchase Agreement

On June 24, 2025, the Company entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Williamsburg Venture Holdings, LLC (the “Purchaser”), whereby the Company has the right, but not the obligation, to sell to the Purchaser, and the Purchaser is obligated to purchase, up to an aggregate of $10.0 million of shares (the “ELOC Shares”) of the Company’s common stock. The term of the Purchase Agreement is the earlier of June 24, 2027, or the date on which the Purchaser has purchased ELOC Shares for an aggregate purchase price of $10.0 million. The Company has also agreed to issue to the Purchaser 426,829 shares common stock (“Commitment Shares”), which will be issued on a pro rata basis as the Company draws down ELOC shares, with any remaining shares to be issued upon termination. The fair value of the Commitment Shares on the date of the Purchase Agreement of $265,957 was established as accrued issuable equity and was expensed, along with approximately $74,000 of additional issuance costs. No shares have been purchased as of December 31, 2025.

Stock-Based Compensation

For the year ended December 31, 2025, the Company recorded stock-based compensation expense of $222,831 (of which, $10,345 was included in research and development and $212,486 was included in general and administrative expense) related to options issued to employees and consultants. As of December 31, 2025, there was $208,316 of unrecognized stock-based compensation expense, which the Company expects to recognize over a weighted average period of 1.9 years.

For the year ended December 31, 2024, the Company recorded stock-based compensation expense of $705,567 (of which, $61,789 was included in research and development and $643,778 was included in general and administrative expense) related to options issued to employees and consultants. As of December 31, 2024, there was $321,893 of unrecognized stock-based compensation expense, which the Company expects to recognize over a weighted average period of 1.3 years.

Stock Options

On July 11, 2025, the Company granted ten-year stock options to purchase 377,964 shares of common stock to employees and directors of the Company under the 2022 Plan. The stock options had an aggregate grant date value of $201,296, vest annually over three years and have an exercise price of $0.59 per share.

The grant date fair value of stock options granted during the years ended December 31, 2025 and 2024 was determined using the Black Scholes method, with the following assumptions used:

Schedule of Stock Options Granted

	For the Years Ended
	December 31,
	2025			2024
Fair value of common stock on date of grant or modification		$0.13 - $0.59		N/A
Risk free interest rate		3.55% - 4.09	%	N/A
Expected term (years)		0.24 - 9.75		N/A
Expected volatility		78.7% - 161.5	%	N/A
Expected dividends		0.00	%	N/A

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

A summary of the option activity for the year ended December 31, 2025 is presented below:

Schedule of Stock Option Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value

Outstanding, January 1, 2025		9,612		$	2,248.58
Granted		377,964			0.59
Exercised		-			-
Expired		(219	)		1,760.50
Outstanding, December 31, 2025		387,357		$	55.67		9.4	$	-

Exercisable, December 31, 2025		8,045		$	2,605.21		5.1	$	-

The following table presents information related to stock options as of December 31, 2025:

Options Outstanding				Options Exercisable
				Weighted
		Outstanding		Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Options		In Years		Options
$	0.59		377,964		-		-
$	152.50		4,157		7.4		2,916
$	738.50		286		7.1		191
$	791.00		38		7.2		26
$	1,760.50		1,060		1.2		1,060
$	3,965.50		37		6.5		37
$	4,053.00		2,095		3.3		2,095
$	5,726.00		1,720		5.5		1,720
			387,357		5.1		8,045

Stock Warrants

On March 7, 2025, the Company closed on a private placement (the “Private Placement”) with an institutional investor, pursuant to which the Company sold pre-funded warrants (the “March 2025 Pre-Funded Warrants”) to purchase 2,105,265 shares of common stock and Series A-3 common warrants (the “March 2025 Common Warrants”) to purchase 2,105,265 shares of common stock at a combined purchase price of $0.9499 which resulted in gross proceeds of approximately $2.0 million. In addition, the Company and the investor executed an amendment to certain November 5, 2024 common share purchase warrants to reduce the exercise price of certain outstanding warrants to purchase 957,200 shares of common stock from $2.06 per share to $1.00 per share. The $53,890 incremental fair value of the modified warrants as compared to the original warrants was recognized as an additional issuance cost of the Private Placement. The March 2025 Pre-Funded Warrants are exercisable immediately, may be exercised at any time until all March 2025 Pre-Funded Warrants are exercised in full, and have an exercise price of $0.0001 per share. As of December 31, 2025, all March 2025 Pre-Funded Warrants were exercised. The March 2025 Common Warrants became exercisable upon Stockholder Approval on June 11, 2025 for a term of five years and have an exercise price of $1.00 per share. Total cash issuance costs were $290,317 including $199,863 of placement fees, $64,312 of legal fees, and $26,142 of other costs.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Warrant Inducement Offer

On July 8, 2025, the Company entered into a warrant exercise inducement offer letter agreement (the “Inducement Letter”) with a holder (the “Holder”) of (i) outstanding Series A-2 common stock purchase warrants, as amended (the “Series A-2 Warrants”), exercisable for up to an aggregate of 957,200 shares of the Company’s common stock, and (ii) Series A-3 common stock purchase warrants (the “Series A-3 Warrants” and together with the Series A-2 Warrants, the “Existing Warrants”) exercisable for up to an aggregate of 2,105,265 shares of common stock, which warrants were originally issued by the Company on November 5, 2024 and March 5, 2025, respectively. The Existing Warrants had an exercise price of $1.00 per share.

The Holder agreed to exercise the Existing Warrants for cash at a reduced exercise price of $0.67 per share in consideration of the Company’s agreement to issue the Holder new warrants to purchase up to a number of shares of common stock equal to 200% of the number of shares of common stock issued pursuant to the Holder’s exercise of Existing Warrants, comprised of new Series A-4 warrants to purchase up to 6,124,930 shares of common stock (the “Inducement Warrants”) at an exercise price of $0.67 per share with an exercise term of 5 years from the initial exercise date. The Company received $2,051,852 in cash proceeds and incurred $175,222 in transaction costs consisting of $133,370 cash fee paid to its financial advisor and $41,852 in other fees. As a result of the reduction in exercise price of the Existing Warrants, the Company recognized a non-cash warrant modification charge of $1,762,756. Because the modification represented a short-term inducement, modification accounting was only performed on the warrants that were actually exercised under the program. The Company recognized the $1,762,756 modification-date incremental value of the modified Existing Warrants and Inducement Warrants issued as compared to the original Existing Warrants, as an issuance cost of the warrant exercise, which was classified as equity with no impact on the consolidated statements of operations. The initial exercise date of the Inducement Warrants is the date that the Company’s stockholders approve the issuance of shares of common stock underlying the warrants (the “Inducement Warrants Shares”) pursuant to the applicable rules and regulations of The Nasdaq Stock Market LLC (“Nasdaq”). On October 6, 2025, Nasdaq filed with the SEC a Form 25, removing and delisting the Company’s securities from Nasdaq. Based on the foregoing and because applicable rules and regulations of the OTC Markets Group Inc. do not require stockholder approval for the issuance of the Inducement Warrant Shares, the Company noted that stockholder approval is no longer required.

The modification date fair value of stock warrants modified during the years ended December 31, 2025 and 2024 was determined using the Black Scholes method, with the following assumptions used:

	For the Years Ended
	December 31,
	2025			2024
Fair value of common stock on date of modification		$0.64 - $0.98			$2.54 - $3.46
Risk free interest rate		3.92% - 4.09	%		3.62% - 4.62	%
Expected term (years)		4.9 - 5.3 years			0.6 - 5.3 years
Expected volatility		125	%		87% - 111	%
Expected dividends		n/a			n/a

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

A summary of the warrant activity for the year ended December 31, 2025 is presented below:

Summary of Warrant Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Warrants			Price		In Years		Value

Outstanding, January 1, 2025		1,747,093		$	59.59
Issued ^[1]		8,230,195			0.75
Repriced - Old ^[2]		(957,200	)		2.06
Repriced - New ^[2]		957,200			1.00
Repriced - Old ^[3]		(957,200	)		1.00
Repriced - New ^[3]		957,200			0.67
Repriced - Old ^[4]		(2,105,265	)		1.00
Repriced - New ^[4]		2,105,265			0.67
Forfeited		(3,050	)		12.50
Exercised^[1]		(3,062,465	)		0.67
Outstanding, December 31, 2025		6,911,773		$	15.34		4.48	$	-

Exercisable, December 31, 2025		6,911,573		$	15.29		4.48	$	-

[1]	Warrants issued and exercised exclude 2,105,265 March 2025 Pre-Funded Warrants with an exercise price of $0.0001.
[2]	Warrants represent the reset of the exercise price of certain November 2024 warrants to purchase 957,200 shares of common stock from $2.06 to $1.00 per share.
[3]	Warrants represent the reset of the exercise price of certain March 2025 warrants to purchase 957,200 shares of common stock from $1.00 to $0.67 per share.
[4]	Warrants represent the reset of the exercise price of certain March 2025 warrants to purchase 2,105,265 shares of common stock from $1.00 to $0.67 per share.

The following table presents information related to stock warrants as of December 31, 2025:

Warrants Outstanding				Warrants Exercisable
		Outstanding		Weighted Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Warrants		In Years		Warrants
$	0.67		6,124,930		4.52		6,124,930
$	2.06		679,800		4.44		679,800
$	12.50		4,050		2.94		4,050
$	47.50		20,347		3.20		20,347
$	57.75		19,965		2.52		19,965
$	350.00		27,551		2.32		27,551
$	700.00		13,944		1.95		13,944
$	1,760.50		200		-		-
$	2,415.00		3,651		1.95		3,651
$	4,025.00		17,335		1.95		17,335
			6,911,773		4.48		6,911,573

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

7,301,269

1,758,844

Warrant [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

^[1]

6,911,773

1,747,093

Share-Based Payment Arrangement, Option [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

387,357

9,612

Series A Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

Series B Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

2,067

[1]

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)

Preferred Stock [Member]

Series A Preferred Stock [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Common Stock [Member]

Treasury Stock, Common [Member]

AOCI Attributable to Parent [Member]

Retained Earnings [Member]

Total

Balance at Dec. 31, 2023

$ 1

$ 40

$ (7,168)

$ 114,300,849

$ (103,219,124)

$ 11,074,598

Balance, shares at Dec. 31, 2023

5,062

405,212

Treasury stock shares at Dec. 31, 2023

(7)

Exercise of warrants

$ 21

2,672,479

2,672,500

Exercise of warrants, shares

213,800

Exercise of pre-funded warrants

$ 13

(13)

Exercise of pre-funded warrants, shares

131,481

Issuance of common stock pursuant to vendor agreements

$ 6

196,764

196,770

Issuance of common stock pursuant to vendor agreements, shares

60,000

Round up share adjustment due to reverse split

$ 8

(8)

Round up share adjustment due to reverse split, shares

75,410

Stock-based compensation

705,567

Warrant inducement offer - exercise proceeds

^[1]

$ 106

(894,631)

(894,525)

Warrant inducement offer - exercise proceeds, shares

^[1]

1,057,800

Warrant modifications

3,033,284

At the market stock issuance

^[2]

$ 57

1,142,245

1,142,302

At the market stock issuance, shares

^[2]

564,495

Shelf registration equity issuance costs

(614)

Net loss

(9,413,435)

Balance at Dec. 31, 2024

$ 1

$ 251

$ (7,168)

121,155,922

(112,632,559)

$ 8,516,447

Balance, shares at Dec. 31, 2024

5,062

2,508,198

Treasury stock shares at Dec. 31, 2024

(7)

Exercise of pre-funded warrants

$ 210

Exercise of pre-funded warrants, shares

2,105,265

Issuance of common stock pursuant to vendor agreements

$ 42

239,958

240,000

Issuance of common stock pursuant to vendor agreements, shares

420,000

Stock-based compensation

222,831

Warrant inducement offer - exercise proceeds

^[3]

$ 306

113,568

113,874

Warrant inducement offer - exercise proceeds, shares

^[3]

3,062,465

Warrant modifications

1,816,646

Net loss

(24,952,378)

Private placement of warrants

^[4]

1,655,584

Balance at Dec. 31, 2025

$ 1

$ 809

$ (7,168)

$ 125,204,509

$ (137,584,937)

$ (12,386,786)

Balance, shares at Dec. 31, 2025

5,062

8,095,928

Treasury stock shares at Dec. 31, 2025

(7)

[1]	Includes gross proceeds of $2,514,088 less issuance costs of $3,408,613
[2]	Includes gross proceeds of $1,354,404 less issuance costs of $212,102
[3]	Includes gross proceeds of $2,051,852 less cash issuance costs of $175,222 and a non-cash warrant modification charge of $1,762,756
[4]	Includes gross proceeds of $1,999,791 less cash issuance costs of $290,317 and a non-cash warrant modification charge of $53,890

Schedule of Provision for Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Current tax benefit:
Federal
State		23,240
Current tax benefit		23,240
Deferred tax benefit:
Federal	(5,062,687)	(1,688,265)
State	(1,127,073)	(164,376)
Deferred tax benefit	(6,189,760)	(1,852,641)
Change in valuation allowance	5,338,101	1,859,386
Provision for income taxes	$ (851,659)	$ 6,745

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Use of Estimates

Cash and Cash Equivalents

Business Combination

Long-Lived Assets

Goodwill and Intangible Assets

Equipment, Net

Deferred Offering Costs

Fair Value of Financial Instruments

Level 1 — quoted prices in active markets for identical assets or liabilities;

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and

Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

The carrying amounts of the Company’s financial instruments, such as cash, accounts payable, and deposits approximate fair values due to the short-term nature of these instruments.

Income Taxes

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

Research and Development

Research and development expenses are charged to operations as incurred.

Stock-Based Compensation

Warrant Classification

Fair Value of Stock Options and Warrants

Net Loss Per Common Share

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

	2025		2024
	For the Years Ended
	December 31,
	2025		2024
Warrants ^[1]		6,911,773		1,747,093
Options		387,357		9,612
Series A Convertible Preferred Stock		72		72
Series B Convertible Preferred Stock		2,067		2,067
Total potentially dilutive shares		7,301,269		1,758,844

[1]

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Vendor Concentration

Segment Reporting

Recently Issued Accounting Pronouncements

Recently Adopted Accounting Pronouncements